Identification

Name
Fusidic Acid
Accession Number
DB02703  (EXPT01507)
Type
Small Molecule
Groups
Approved, Investigational
Description

An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed) It acts by inhibiting translocation during protein synthesis.

Structure
Thumb
Synonyms
  • Fucidate
  • Fucidin acid
  • Fusidate
  • Fusidic acid
  • Fusidine
  • Ramycin
External IDs
NSC-56192 / SQ 16,603 / SQ-16603
Product Ingredients
IngredientUNIICASInChI Key
Fucidate SodiumJ7P3696BCQ751-94-0HJHVQCXHVMGZNC-JCJNLNMISA-M
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Fucidin Cream 2%Cream2 %TopicalLeo Pharma1984-12-31Not applicableCanada
Fucidin Film Coated Tab 250mgTablet250 mgOralLeo Pharma1991-12-312009-06-05Canada
Fucidin Intertulle 2%Dressing2 %TopicalLeo Pharma1984-12-312004-07-23Canada
Fucidin Leo Sus 246mg/5mlSuspension246 mgOralLeo Pharma1980-12-312004-07-23Canada
Fucidin Ointment 2%Ointment2 %TopicalLeo Pharma1984-12-31Not applicableCanada
FucithalmicSolution / drops1 %OphthalmicAmdipharm Limited2001-08-29Not applicableCanada
FucithalmicSolution / drops1 %OphthalmicAmdipharm Limited2001-08-072017-07-17Canada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
FucibetFusidic Acid (2 %) + Betamethasone (0.1 %)CreamTopicalLeo PharmaNot applicableNot applicableCanada
Fucidin HFusidic Acid (2 %) + Hydrocortisone acetate (1 %)CreamTopicalLeo Pharma1998-11-11Not applicableCanada
Fucidin Leo Injection KitFucidate Sodium (500 mg) + Sodium phosphate, dibasic (10 ml)KitIntravenousLeo Pharma1984-12-312004-08-01Canada
International/Other Brands
Fucidin / Fucidine / Fudic / Taksta
Categories
UNII
59XE10C19C
CAS number
6990-06-3
Weight
Average: 516.7092
Monoisotopic: 516.345089268
Chemical Formula
C31H48O6
InChI Key
IECPWNUMDGFDKC-MZJAQBGESA-N
InChI
InChI=1S/C31H48O6/c1-17(2)9-8-10-20(28(35)36)26-22-15-24(34)27-29(5)13-12-23(33)18(3)21(29)11-14-30(27,6)31(22,7)16-25(26)37-19(4)32/h9,18,21-25,27,33-34H,8,10-16H2,1-7H3,(H,35,36)/b26-20-/t18-,21-,22-,23+,24+,25-,27-,29-,30-,31-/m0/s1
IUPAC Name
2-[(1S,2S,5R,6S,7S,10S,11S,13S,14Z,15R,17R)-13-(acetyloxy)-5,17-dihydroxy-2,6,10,11-tetramethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-14-ylidene]-6-methylhept-5-enoic acid
SMILES
O[C@@H]1CC[C@@]2(C)[C@@]([H])(CC[C@@]3(C)[C@@]2([H])[C@H](O)C[C@@]2([H])\C([C@@H](OC(=O)C)C[C@]32C)=C(/CCC=C(C)C)C(O)=O)[C@@H]1C

Pharmacology

Indication

For the treatment of bacterial infections.

Associated Conditions
Pharmacodynamics

Fusidic acid is a bacteriostatic antibiotic that is often used topically in creams and eyedrops, but may also be given systemically as tablets or injections.

Mechanism of action

Fusidic acid works by interfering with bacterial protein synthesis, specifically by preventing the translocation of the elongation factor G (EF-G) from the ribosome. It also can inhibit chloramphenicol acetyltransferase enzymes.

TargetActionsOrganism
AElongation factor G
inhibitor
Thermus thermophilus
UChloramphenicol acetyltransferase
inhibitor
Salmonella typhi
UChloramphenicol acetyltransferase 3
inhibitor
Escherichia coli
Absorption

Sodium fusidic acid tablets have a 91% oral bioavailability. Absorption of the film-coated tablets is complete when compared to a solution, however oral absorption is variable. Oral fusidic acid hemihydrate (suspension) achieved a 22.5% bioavailability in pediatric patients following a 20 milligram/kilogram dose.

Volume of distribution
Not Available
Protein binding

97 to 99%

Metabolism

Metabolites include dicarboxylic ester/acid, 3-keto fusidic acid, hydroxy fusidic acid, glucuronide fusidic acid and a glycol metabolite.

Route of elimination
Not Available
Half life

Approximately 5 to 6 hours in adults.

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Enteric bacteria and other eubacteria
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with Fusidic Acid.
AbirateroneThe serum concentration of Abiraterone can be increased when it is combined with Fusidic Acid.
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Fusidic Acid.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Fusidic Acid.
AcetazolamideThe metabolism of Fusidic Acid can be decreased when combined with Acetazolamide.
AdenineThe metabolism of Fusidic Acid can be decreased when combined with Adenine.
AdinazolamThe serum concentration of Adinazolam can be increased when it is combined with Fusidic Acid.
AgmatineThe serum concentration of Agmatine can be increased when it is combined with Fusidic Acid.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Fusidic Acid.
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Fusidic Acid.
Food Interactions
  • Take with food to reduce irritation.

References

Synthesis Reference

Vanangamudi Subramaniam Sulur, Madhavan Srinivasan, Neelakandan Narayanan Chulliel, Haridas Sankar, Selvaraj Balkrishnan, " PROCESS TO MAKE FUSIDIC ACID CREAM." U.S. Patent US20110301138, issued December 08, 2011.

US20110301138
General References
Not Available
External Links
Human Metabolome Database
HMDB0015570
KEGG Drug
D04281
KEGG Compound
C06694
PubChem Compound
3000226
PubChem Substance
46505364
ChemSpider
2271900
BindingDB
58924
ChEBI
29013
ChEMBL
CHEMBL374975
Therapeutic Targets Database
DAP001008
PharmGKB
PA164749648
HET
FUA
Wikipedia
Fusidic_acid
ATC Codes
J01XC01 — Fusidic acidD09AA02 — Fusidic acidD06AX01 — Fusidic acidS01AA13 — Fusidic acid
AHFS Codes
  • 52:04.04 — Antibacterials
  • 84:04.04 — Antibiotics
  • 08:12.28.92 — Other Miscellaneous Antibacterial Agents*
PDB Entries
1q23 / 1qca / 2vuf / 4v5f / 4v5m / 4v5n / 4v7b / 4v8u / 4v9l / 4v9m
show 2 more

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentSkin Diseases, Bacterial1
2TerminatedTreatmentInfected Spacers / Prosthetic Joint Infections of Hip / Prosthetic Joint Infections of Knee1
2, 3Active Not RecruitingTreatmentRefractory Bone or Joint Infections1
3CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
3RecruitingTreatmentInfected Atopic Dermatitis/Eczema1
3Unknown StatusPreventionHypertrophic Scars / Keloid Scars1
4Enrolling by InvitationTreatmentInflammation of the Eyelids1
4TerminatedTreatmentImpetigo1
Not AvailableCompletedNot AvailableImpetigo1
Not AvailableRecruitingPreventionMotility Disorders / Staphylococcus Aureus1
Not AvailableRecruitingTreatmentProsthetic Joint Infection1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CreamTopical2 %
TabletOral250 mg
CreamTopical
DressingTopical2 %
KitIntravenous
SuspensionOral246 mg
OintmentTopical2 %
Solution / dropsOphthalmic1 %
Prices
Unit descriptionCostUnit
Fucidin 2 % Cream0.66USD g
Fucidin 2 % Ointment0.66USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)192.5 °CPhysProp
pKa5.35MERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility0.00521 mg/mLALOGPS
logP4.97ALOGPS
logP4.42ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)4.66ChemAxon
pKa (Strongest Basic)-0.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area104.06 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity144.12 m3·mol-1ChemAxon
Polarizability59.77 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9691
Blood Brain Barrier+0.7909
Caco-2 permeable-0.6089
P-glycoprotein substrateSubstrate0.8165
P-glycoprotein inhibitor INon-inhibitor0.6004
P-glycoprotein inhibitor IIInhibitor0.7848
Renal organic cation transporterNon-inhibitor0.8424
CYP450 2C9 substrateNon-substrate0.8218
CYP450 2D6 substrateNon-substrate0.9349
CYP450 3A4 substrateSubstrate0.798
CYP450 1A2 substrateNon-inhibitor0.9337
CYP450 2C9 inhibitorNon-inhibitor0.8834
CYP450 2D6 inhibitorNon-inhibitor0.9544
CYP450 2C19 inhibitorNon-inhibitor0.9347
CYP450 3A4 inhibitorNon-inhibitor0.76
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.819
Ames testNon AMES toxic0.8305
CarcinogenicityNon-carcinogens0.9508
BiodegradationNot ready biodegradable0.9753
Rat acute toxicity3.5929 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9403
hERG inhibition (predictor II)Non-inhibitor0.7564
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-05fr-0002900000-512150f35d55c73b9e09
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-004i-0000900000-eecd35dcbd3fede944c2
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-0002-0000900000-4a266f99ada066a14539

Taxonomy

Description
This compound belongs to the class of organic compounds known as steroid esters. These are compounds containing a steroid moiety which bears a carboxylic acid ester group.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Steroid esters
Direct Parent
Steroid esters
Alternative Parents
3-alpha-hydroxysteroids / 11-alpha-hydroxysteroids / Medium-chain fatty acids / Methyl-branched fatty acids / Hydroxy fatty acids / Unsaturated fatty acids / Dicarboxylic acids and derivatives / Secondary alcohols / Cyclic alcohols and derivatives / Carboxylic acid esters
show 4 more
Substituents
Steroid ester / 3-hydroxysteroid / 3-alpha-hydroxysteroid / 11-hydroxysteroid / 11-alpha-hydroxysteroid / Hydroxysteroid / Medium-chain fatty acid / Branched fatty acid / Methyl-branched fatty acid / Hydroxy fatty acid
show 16 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
3alpha-hydroxy steroid, alpha,beta-unsaturated monocarboxylic acid, sterol ester, steroid acid, 11alpha-hydroxy steroid, steroid antibiotic (CHEBI:29013) / Prostostane and fusidane triterpenoids (LMPR0106040001)

Targets

Kind
Protein
Organism
Thermus thermophilus
Pharmacological action
Yes
Actions
Inhibitor
General Function
Translation elongation factor activity
Specific Function
Catalyzes the GTP-dependent ribosomal translocation step during translation elongation. During this step, the ribosome changes from the pre-translocational (PRE) to the post-translocational (POST) ...
Gene Name
fusA
Uniprot ID
P13551
Uniprot Name
Elongation factor G
Molecular Weight
76878.69 Da
References
  1. Lannergard J, Norstrom T, Hughes D: Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus. Antimicrob Agents Chemother. 2009 May;53(5):2059-65. doi: 10.1128/AAC.00871-08. Epub 2009 Mar 16. [PubMed:19289529]
  2. Chen Y, Koripella RK, Sanyal S, Selmer M: Staphylococcus aureus elongation factor G--structure and analysis of a target for fusidic acid. FEBS J. 2010 Sep;277(18):3789-803. doi: 10.1111/j.1742-4658.2010.07780.x. Epub 2010 Aug 13. [PubMed:20718859]
  3. Gao YG, Selmer M, Dunham CM, Weixlbaumer A, Kelley AC, Ramakrishnan V: The structure of the ribosome with elongation factor G trapped in the posttranslocational state. Science. 2009 Oct 30;326(5953):694-9. doi: 10.1126/science.1179709. [PubMed:19833919]
Kind
Protein
Organism
Salmonella typhi
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Chloramphenicol o-acetyltransferase activity
Specific Function
This enzyme is an effector of chloramphenicol resistance in bacteria.
Gene Name
cat
Uniprot ID
P62580
Uniprot Name
Chloramphenicol acetyltransferase
Molecular Weight
25663.08 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Murray IA, Cann PA, Day PJ, Derrick JP, Sutcliffe MJ, Shaw WV, Leslie AG: Steroid recognition by chloramphenicol acetyltransferase: engineering and structural analysis of a high affinity fusidic acid binding site. J Mol Biol. 1995 Dec 15;254(5):993-1005. [PubMed:7500366]
  4. Bennett AD, Shaw WV: Resistance to fusidic acid in Escherichia coli mediated by the type I variant of chloramphenicol acetyltransferase. A plasmid-encoded mechanism involving antibiotic binding. Biochem J. 1983 Oct 1;215(1):29-38. [PubMed:6354181]
  5. Day PJ, Murray IA, Shaw WV: Properties of hybrid active sites in oligomeric proteins: kinetic and ligand binding studies with chloramphenicol acetyltransferase trimers. Biochemistry. 1995 May 16;34(19):6416-22. [PubMed:7756272]
Kind
Protein
Organism
Escherichia coli
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Chloramphenicol o-acetyltransferase activity
Specific Function
This enzyme is an effector of chloramphenicol resistance in bacteria.
Gene Name
cat3
Uniprot ID
P00484
Uniprot Name
Chloramphenicol acetyltransferase 3
Molecular Weight
24993.32 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Murray IA, Cann PA, Day PJ, Derrick JP, Sutcliffe MJ, Shaw WV, Leslie AG: Steroid recognition by chloramphenicol acetyltransferase: engineering and structural analysis of a high affinity fusidic acid binding site. J Mol Biol. 1995 Dec 15;254(5):993-1005. [PubMed:7500366]
  4. Bennett AD, Shaw WV: Resistance to fusidic acid in Escherichia coli mediated by the type I variant of chloramphenicol acetyltransferase. A plasmid-encoded mechanism involving antibiotic binding. Biochem J. 1983 Oct 1;215(1):29-38. [PubMed:6354181]
  5. Day PJ, Murray IA, Shaw WV: Properties of hybrid active sites in oligomeric proteins: kinetic and ligand binding studies with chloramphenicol acetyltransferase trimers. Biochemistry. 1995 May 16;34(19):6416-22. [PubMed:7756272]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Lin XX, Lian GH, Xu Y, Zhao Q, Xiao J, Peng SF, Xiao MF, Ouyang DS, Tan ZR, Wang YC, Peng JB, Zhang W, Chen Y: The potent mechanism-based inactivation of CYP2D6 and CYP3A4 with fusidic acid in in vivo bioaccumulation. Xenobiotica. 2018 Oct;48(10):999-1005. doi: 10.1080/00498254.2017.1390628. Epub 2017 Nov 10. [PubMed:29027845]
  2. Chen D, Lin XX, Zhao Q, Xiao J, Peng SF, Xiao MF, Ouyang DS, Tan ZR, Wang YC, Peng JB, Zhang W, Chen Y: Screening of drug metabolizing enzymes for fusidic acid and its interactions with isoform-selective substrates in vitro. Xenobiotica. 2017 Sep;47(9):778-784. doi: 10.1080/00498254.2016.1230795. Epub 2016 Nov 15. [PubMed:27571049]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Lin XX, Lian GH, Xu Y, Zhao Q, Xiao J, Peng SF, Xiao MF, Ouyang DS, Tan ZR, Wang YC, Peng JB, Zhang W, Chen Y: The potent mechanism-based inactivation of CYP2D6 and CYP3A4 with fusidic acid in in vivo bioaccumulation. Xenobiotica. 2018 Oct;48(10):999-1005. doi: 10.1080/00498254.2017.1390628. Epub 2017 Nov 10. [PubMed:29027845]
  2. Chen D, Lin XX, Zhao Q, Xiao J, Peng SF, Xiao MF, Ouyang DS, Tan ZR, Wang YC, Peng JB, Zhang W, Chen Y: Screening of drug metabolizing enzymes for fusidic acid and its interactions with isoform-selective substrates in vitro. Xenobiotica. 2017 Sep;47(9):778-784. doi: 10.1080/00498254.2016.1230795. Epub 2016 Nov 15. [PubMed:27571049]
  3. Gupta A, Harris JJ, Lin J, Bulgarelli JP, Birmingham BK, Grimm SW: Fusidic Acid Inhibits Hepatic Transporters and Metabolic Enzymes: Potential Cause of Clinical Drug-Drug Interaction Observed with Statin Coadministration. Antimicrob Agents Chemother. 2016 Sep 23;60(10):5986-94. doi: 10.1128/AAC.01335-16. Print 2016 Oct. [PubMed:27458210]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
References
  1. Gupta A, Harris JJ, Lin J, Bulgarelli JP, Birmingham BK, Grimm SW: Fusidic Acid Inhibits Hepatic Transporters and Metabolic Enzymes: Potential Cause of Clinical Drug-Drug Interaction Observed with Statin Coadministration. Antimicrob Agents Chemother. 2016 Sep 23;60(10):5986-94. doi: 10.1128/AAC.01335-16. Print 2016 Oct. [PubMed:27458210]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Bode KA, Donner MG, Leier I, Keppler D: Inhibition of transport across the hepatocyte canalicular membrane by the antibiotic fusidate. Biochem Pharmacol. 2002 Jul 1;64(1):151-8. [PubMed:12106615]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Bode KA, Donner MG, Leier I, Keppler D: Inhibition of transport across the hepatocyte canalicular membrane by the antibiotic fusidate. Biochem Pharmacol. 2002 Jul 1;64(1):151-8. [PubMed:12106615]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Gupta A, Harris JJ, Lin J, Bulgarelli JP, Birmingham BK, Grimm SW: Fusidic Acid Inhibits Hepatic Transporters and Metabolic Enzymes: Potential Cause of Clinical Drug-Drug Interaction Observed with Statin Coadministration. Antimicrob Agents Chemother. 2016 Sep 23;60(10):5986-94. doi: 10.1128/AAC.01335-16. Print 2016 Oct. [PubMed:27458210]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. Gupta A, Harris JJ, Lin J, Bulgarelli JP, Birmingham BK, Grimm SW: Fusidic Acid Inhibits Hepatic Transporters and Metabolic Enzymes: Potential Cause of Clinical Drug-Drug Interaction Observed with Statin Coadministration. Antimicrob Agents Chemother. 2016 Sep 23;60(10):5986-94. doi: 10.1128/AAC.01335-16. Print 2016 Oct. [PubMed:27458210]

Drug created on June 13, 2005 07:24 / Updated on October 16, 2018 08:37